Arkolith/Insider Trading/VKTX/Form 4

Rowland Charles A Jr

DirectorViking Therapeutics, Inc. (VKTX) · full profile →Form 4 · filed Oct 28, 2025
Net Selling
Open-Market Buys
$0
Open-Market Sells
$2.1M
Net Open-Market Flow
-$2.1M
Transactions
7
4 non-derivative · 3 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Oct 27, 2025Sell(S)60K$35.57$2.1M30K
Oct 27, 2025Grant(A)22K$4.88$107K90K
Oct 27, 2025Grant(A)22K$5.80$128K68K
Oct 27, 2025Grant(A)16K$4.48$72K46K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Oct 27, 2025Option exercise(M)22K—$00
Oct 27, 2025Option exercise(M)22K—$00
Oct 27, 2025Option exercise(M)16K—$00

Transaction Codes

S
Open-market sale
A
Grant / award
M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001193125-25-254300) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML